187 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00704 | 10a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 28 µM |
| dbacp00705 | 10b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.4 µM |
| dbacp00706 | 10c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.6 µM |
| dbacp00707 | 11a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 5.2 µM |
| dbacp00708 | 11b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 19 µM |
| dbacp00709 | 11c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.2 µM |
| dbacp00710 | 12a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.1 µM |
| dbacp00711 | 12b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 27 µM |
| dbacp00712 | 12c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14 µM |
| dbacp00722 | 5a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10.6 µM |
| dbacp00723 | 5b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.1 µM |
| dbacp00724 | 5c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.1 µM |
| dbacp00727 | 6a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14.4 µM |
| dbacp00728 | 6b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.0 µM |
| dbacp00729 | 6c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.3 µM |
| dbacp00730 | 7a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >63 µM |
| dbacp00731 | 7b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >78 µM |
| dbacp00732 | 7c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 79 µM |
| dbacp00733 | 8a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 136 µM |
| dbacp00734 | 8b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >254 µM |
| dbacp00735 | 8c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 107 µM |
| dbacp00736 | 9a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 31 µM |
| dbacp00737 | 9b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 2.3 µM |
| dbacp00738 | 9c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.1 µM |
| dbacp01933 | Brevinin-1BW | FLPLLAGLAASFLPTIFCKISRKC | Skin, Black-spotted Frog, East Asia | Disruption of cell membrane | Not specified | Not found | Not found | Not found |
| dbacp02375 | CecropinXJ | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | Larvae, Domestic silk moth | Disruption of cell membrane | Not specified | Not found | Not found | Not found |
| dbacp02627 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : 3.2 ± 0.6 µM |
| dbacp02628 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | IC50 : 4.5 ± 0.5 µM |
| dbacp02629 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 4.7 ± 0.4 µM |
| dbacp02630 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 3.2 ± 0.4 µM |
| dbacp02688 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 17.44 - 49.51 μM |
| dbacp02689 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02690 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02691 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02692 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 17.44 - 49.51 μM |
| dbacp02693 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Brain tumor | IC50 : 7.44 μM |
| dbacp02694 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 7.44 μM |
| dbacp02695 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | pancreatic cancer | IC50 : 7.44 μM |
| dbacp02696 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 7.44 μM |
| dbacp02697 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 7.44 μM |
| dbacp02698 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Brain tumor | IC50 : 49.51 μM |
| dbacp02699 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 49.51 μM |
| dbacp02700 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 49.51 μM |
| dbacp02701 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 49.51 μM |
| dbacp02702 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 49.51 μM |
| dbacp02703 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Brain tumor | IC50 : 25.51 μM |
| dbacp02704 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 25.51 μM |
| dbacp02705 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 25.51 μM |
| dbacp02706 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 25.51 μM |
| dbacp02707 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 25.51 μM |
| dbacp02708 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 21.78 μM |
| dbacp02709 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 21.78 μM |
| dbacp02710 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 21.78 μM |
| dbacp02711 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 21.78 μM |
| dbacp02712 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 21.78 μM |
| dbacp02713 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 28.95 μM |
| dbacp02714 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 28.95 μM |
| dbacp02715 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 28.95 μM |
| dbacp02716 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 28.95 μM |
| dbacp02717 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 28.95 μM |
| dbacp02718 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Brain tumor | IC50 : 51.04 μM |
| dbacp02719 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 51.04 μM |
| dbacp02720 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 51.04 μM |
| dbacp02721 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 51.04 μM |
| dbacp02722 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 51.04 μM |
| dbacp02731 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 8.64 - 18.51 μM |
| dbacp02732 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02733 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02734 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02735 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp02736 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | U251MG | Neuronal glioblastoma | IC50 : 8.64 - 18.51 μM |
| dbacp02737 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02738 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02739 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | NCl-H157 | Lung cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02740 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp03485 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Brain tumor | IC50 : 8.64μM |
| dbacp03486 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 8.64μM |
| dbacp03487 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Pancreatic cancer | IC50 : 8.64μM |
| dbacp03488 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Lung cancer | IC50 : 8.64μM |
| dbacp03489 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 8.64μM |
| dbacp03490 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Brain tumor | IC50 : 18.51μM |
| dbacp03491 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 18.51μM |
| dbacp03492 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 18.51μM |
| dbacp03493 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Lung cancer | IC50 : 18.51μM |
| dbacp03494 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 18.51μM |
| dbacp03495 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Brain tumor | IC50 : 9.88μM |
| dbacp03496 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 9.88μM |
| dbacp03497 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 9.88μM |
| dbacp03498 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Lung cancer | IC50 : 9.88μM |
| dbacp03499 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 9.88μM |
| dbacp03500 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 9.97μM |
| dbacp03501 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 9.97μM |
| dbacp03502 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 9.97μM |
| dbacp03503 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 9.97μM |
| dbacp03504 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 9.97μM |
| dbacp03505 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Brain tumor | IC50 : 11.17μM |
| dbacp03506 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 11.17μM |
| dbacp03507 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 11.17μM |
| dbacp03508 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Lung cancer | IC50 : 11.17μM |
| dbacp03509 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 11.17μM |
| dbacp03510 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Brain tumor | IC50 : 48.80μM |
| dbacp03511 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 48.80μM |
| dbacp03512 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 48.80μM |
| dbacp03513 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Lung cancer | IC50 : 48.80μM |
| dbacp03514 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 48.80μM |
| dbacp03676 | Lasioglossin LL-I | VNWKKVLGKIIKVAK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | LC50 : > 200 µM |
| dbacp03677 | Lasioglossin LL-I | VNWKKVLGKIIKVAK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | Not found |
| dbacp03679 | Lasioglossin LL-II | VNWKKILGKIIKVAK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | LC50 : > 200 µM |
| dbacp03680 | Lasioglossin LL-II | VNWKKILGKIIKVAK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | Not found |
| dbacp03688 | Lasioglossin LL-III | VNWKKILGKIIKVVK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | LC50 : > 200 µM |
| dbacp03689 | Lasioglossin LL-III | VNWKKILGKIIKVVK | The Eusocial Bee, Broad-faced Furrow Bee | Disruption of cell membrane | Not specified | Not found | Not specified | Not found |
| dbacp05525 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05526 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05527 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05528 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05529 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05530 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05531 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.29 µM |
| dbacp05532 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05533 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05534 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05535 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U251MG | Neurospongioma | IC50 : approx. 0.29 µM |
| dbacp05536 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05537 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05538 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05539 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H838 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05540 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H460 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05541 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H23 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05542 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | H157 | Lung cancer | IC50 : approx. 0.50 µM |
| dbacp05543 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05544 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05545 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05546 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U251MG | neurospongioma | IC50 : approx. 0.50 µM |
| dbacp06154 | StigA16 | FFKLIPKLVKGLISAF | Amino acid substitution, amino acid truncation, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | 3T3 | Renal cell adenocarcinoma | IC 50 : 13.01 μM |
| dbacp06155 | StigA16 | FFKLIPKLVKGLISAF | Amino acid substitution, amino acid truncation, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | HeLa | Mouse melanoma | IC 50 : 13.01 μM |
| dbacp06156 | StigA16 | FFKLIPKLVKGLISAF | Amino acid substitution, amino acid truncation, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | 786-0 | Human cervix adenocarcinoma | IC 50 : 13.01 μM |
| dbacp06157 | StigA16 | FFKLIPKLVKGLISAF | Amino acid substitution, amino acid truncation, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | B16 | Human pancreas adenocarcinoma | IC 50 : 13.01 μM |
| dbacp06158 | StigA16 | FFKLIPKLVKGLISAF | Amino acid substitution, amino acid truncation, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | Panc | Mouse fibroblast | IC 50 : 13.01 μM |
| dbacp06159 | StigA6 | FFSLIPKLVKGLISAFK | Amino acid substitution, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | 3T3 | Renal cell adenocarcinoma | IC 50 : 14.01 μM |
| dbacp06160 | StigA6 | FFSLIPKLVKGLISAFK | Amino acid substitution, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | HeLa | Mouse melanoma | IC 50 : 14.01 μM |
| dbacp06161 | StigA6 | FFSLIPKLVKGLISAFK | Amino acid substitution, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | 786-0 | Human cervix adenocarcinoma | IC 50 : 14.01 μM |
| dbacp06162 | StigA6 | FFSLIPKLVKGLISAFK | Amino acid substitution, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | B16 | Human pancreas adenocarcinoma | IC 50 : 14.01 μM |
| dbacp06163 | StigA6 | FFSLIPKLVKGLISAFK | Amino acid substitution, animal-derived, natural derivative | Disruption of cell membrane | MTT assay | Panc | Mouse fibroblast | IC 50 : 14.01 μM |
| dbacp06169 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | Not found |
| dbacp06170 | SVS-1 | KVKVKVKVpPTKVKVKVK | Bovine lactoferrin (Lf-B) | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | Not found |
| dbacp06171 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 8.1 ± 0.8 µM |
| dbacp06172 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 5.6 ± 0.5 µM |
| dbacp06173 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µM |
| dbacp06174 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | IC50 : >100 µM |
| dbacp06175 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µM |
| dbacp06176 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : >100 µM |
| dbacp06388 | Turgencin B | GIKEML_CnMACAQTVC_KKSGGPLCDTCQAACKALG-NH2 | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 4.1μM |
| dbacp06389 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06390 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV-NH2 | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06391 | Turgencin A | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Tunicate | Disruption of cell membranes | Human cell viability assay | A2058 | Melanoma cancer | IC50 : 1.4 μM |
| dbacp06392 | Turgencin B | GIKEMLCnMACAQTVCKKSGGPLCDTCQAACKALG | Tunicate | Disruption of cell membranes | Human cell viability assay | A2059 | Melanoma cancer | IC50 : 4.1 μM |
| dbacp06393 | Turgencin B | GIKEMLCnMACAQTVCKKSGGPLCDTCQAACKALG | Tunicate | Disruption of cell membranes | Human cell viability assay | A2059 | Melanoma cancer | IC50 : 4.1 μM |
| dbacp06548 | Z1 | KAAKKWAKAAKKAAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : > 211 µM |
| dbacp06549 | Z1 | KAAKKWAKAAKKWAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 186 µM |
| dbacp06550 | Z1 | KAAKKWAKAAKKWAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : > 211 µM |
| dbacp06551 | Z10 | AAKKWAKAKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : > 211 µM |
| dbacp06552 | Z10 | AAKKWAKAKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : > 211 µM |
| dbacp06553 | Z10 | AAKKWAKAKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : > 211 µM |
| dbacp06554 | Z2 | KAAKKWAKAWKKAAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : > 211 µM |
| dbacp06555 | Z2 | KAAKKWAKAWKKAAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 173 µM |
| dbacp06556 | Z2 | KAAKKWAKAWKKAAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : > 211 µM |
| dbacp06567 | Z3 | KAAKKAWKAWKKAAKAAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : >211 µM |
| dbacp06568 | Z3 | KAAKKAWKAWKKAAKAAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 128 µM |
| dbacp06569 | Z3 | KAAKKAWKAWKKAAKAAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : >211 µM |
| dbacp06570 | Z4 | KAAKKAWKAAKKAAKWWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 155 µM |
| dbacp06571 | Z4 | KAAKKAWKAAKKAAKWWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 68 µM |
| dbacp06572 | Z4 | KAAKKAWKAAKKAAKWWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 173 µM |
| dbacp06583 | Z5 | KAAKKAWKWAKKAAKWAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 42 µM |
| dbacp06584 | Z5 | KAAKKAWKWAKKAAKWAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 28 µM |
| dbacp06585 | Z5 | KAAKKAWKWAKKAAKWAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 67 µM |
| dbacp06586 | Z6 | KWWKKAAKAAKKAAKAAKKWA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 17 µM |
| dbacp06587 | Z6 | KWWKKAAKAAKKAAKAAKKWA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 16 µM |
| dbacp06588 | Z6 | KWWKKAAKAAKKAAKAAKKWA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 31 µM |
| dbacp06589 | Z7 | KAAKKAWKAAKKAWKAAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 15 µM |
| dbacp06590 | Z7 | KAAKKAWKAAKKAWKAAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 15 µM |
| dbacp06591 | Z7 | KAAKKAWKAAKKAWKAAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 21 µM |
| dbacp06592 | Z8 | AWKKWAKAWKWAKAKWWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 19 µM |
| dbacp06593 | Z8 | AWKKWAKAWKWAKAKWWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 14 µM |
| dbacp06594 | Z8 | AWKKWAKAWKWAKAKWWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 23 µM |
| dbacp06595 | Z9 | AAWKWAWAKKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | Meth A | Skin cancer | EC50 : 9 µM |
| dbacp06596 | Z9 | AAWKWAWAKKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 16 µM |
| dbacp06597 | Z9 | AAWKWAWAKKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | HT-29 | Colon cancer | EC50 : 13 µM |